AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22291116 — intervention group
Group type: COMPARATOR
Intervention: NCPAP with medical air (control group)
Number of subjects: 51
Study 19896176 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate voltage escalation SWL
Number of subjects: 160
Study 19896176 — intervention group
Group type: COMPARATOR
Intervention: Delayed voltage escalation SWL
Number of subjects: 160
Study 17362372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intergroup competition
Number of subjects: 0
Study 17362372 — intervention group
Group type: COMPARATOR
Intervention: No intergroup competition
Number of subjects: 0
Study 16278614 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg of estradiol acetate (n = 79)
Number of subjects: 249
Study 16278614 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of micronized estradiol (n = 85)
Number of subjects: 249
Study 16278614 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogens (n = 85)
Number of subjects: 249
Study 12192282 — intervention group
Group type: EXPERIMENTAL
Intervention: I-123 MIBG imaging
Number of subjects: 29
Study 12192282 — intervention group
Group type: EXPERIMENTAL
Intervention: I-123 BMIPP imaging
Number of subjects: 29
Study 12192282 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced stress perfusion imaging
Number of subjects: 29
Study 12192282 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial biopsy
Number of subjects: 29
Study 10205099 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg a day for 12 weeks (T12)
Number of subjects: 496
Study 10205099 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg a day for 16 weeks (T16)
Number of subjects: 496
Study 10205099 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 400 mg a day for 1 week in every 4 weeks for 12 weeks (I3)
Number of subjects: 496
Study 10205099 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 400 mg a day for 1 week in every 4 weeks for 16 weeks (I4)
Number of subjects: 496
Study 7845310 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a
Number of subjects: 62
Study 7845310 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Number of subjects: 62
Study 7845310 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (combined data)
Number of subjects: 62
Study 1960382 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam
Number of subjects: 31
Study 1960382 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 31
Study 7148742 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day diet records
Number of subjects: 107
Study 7148742 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day diet records
Number of subjects: 107
Study 7148742 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-h recalls
Number of subjects: 107
Study 7148742 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h recalls
Number of subjects: 107
Study 7148742 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer
Number of subjects: 107
Study 31865785 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril plus folic acid
Number of subjects: 19053
Study 31865785 — intervention group
Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 19053
Study 30522343 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/d)
Number of subjects: 251
Study 30522343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 28821597 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐DCT (electronic discharge communication tool)
Number of subjects: 1399
Study 28821597 — intervention group
Group type: COMPARATOR
Intervention: Usual care (traditional discharge communication)
Number of subjects: 1399
Study 28821597 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐DCT
Number of subjects: 1399
Study 28821597 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1399
Study 27631380 — intervention group
Group type: EXPERIMENTAL
Intervention: House Calls (HC) educational intervention
Number of subjects: 152
Study 27631380 — intervention group
Group type: COMPARATOR
Intervention: Individual Counseling (IC)
Number of subjects: 152
Study 27631380 — intervention group
Group type: COMPARATOR
Intervention: Group-Based (GB) intervention
Number of subjects: 152
Study 24533792 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (one-day intensive training, poster presentation, regular visits, reminder messages over 4 weeks)
Number of subjects: 100
Study 24533792 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 100
Study 24533792 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 23018300 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-row 3-D linear cutter (N group)
Number of subjects: 41
Study 23018300 — intervention group
Group type: COMPARATOR
Intervention: Standard 4-row linear cutter (S group)
Number of subjects: 41
Study 20308833 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg gestrinone
Number of subjects: 998
Study 20308833 — intervention group
Group type: COMPARATOR
Intervention: 10 mg mifepristone
Number of subjects: 998
Study 17678655 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit class therapy
Number of subjects: 68
Study 17678655 — intervention group
Group type: COMPARATOR
Intervention: Individual physiotherapy sessions
Number of subjects: 68
Study 15333619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad hoc imputation methods
Number of subjects: 0
Study 15333619 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard multiple imputation
Number of subjects: 0
Study 15333619 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal modelling
Number of subjects: 0
Study 15333619 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifying the modelling method for non-ignorable dropout
Number of subjects: 0
Study 15333619 — intervention group
Group type: EXPERIMENTAL
Intervention: Common imputation model in both groups
Number of subjects: 0
Study 12230417 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of estrogen with progestin
Number of subjects: 726
Study 12230417 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of estrogen without progestin
Number of subjects: 726
Study 12230417 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone use (first 6 months)
Number of subjects: 726
Study 12230417 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen dose
Number of subjects: 726
Study 10219357 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental telephone management educational program using a standardized patient (SP)
Number of subjects: 0
Study 10219357 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback to the experimental group
Number of subjects: 0
Study 7606199 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 800 mg/m2/day
Number of subjects: 26
Study 7606199 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 26
Study 2114050 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-made powder product (group 1)
Number of subjects: 40
Study 2114050 — intervention group
Group type: COMPARATOR
Intervention: Ready-made sterile standard tube-feeding product: Salvimulsin MCT (group 2)
Number of subjects: 40
Study 856022 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin
Number of subjects: 0
Study 856022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 0
Study 856022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 0
Study 856022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 0
Study 856022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 0
Study 856022 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 0
Study 856022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 0
Study 856022 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 0
Study 31709910 — intervention group
Group type: EXPERIMENTAL
Intervention: SOLE MATES program (six face-to-face sessions over six weeks)
Number of subjects: 58
Study 30366744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine and haloperidol
Number of subjects: 140
Study 30366744 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine with normal saline (Control)
Number of subjects: 140
Study 26096021 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 42
Study 25936892 — intervention group
Group type: EXPERIMENTAL
Intervention: NAV method (electromagnetically-guided navigation system)
Number of subjects: 54
Study 25936892 — intervention group
Group type: COMPARATOR
Intervention: CT-guidance (standard computed tomography guidance)
Number of subjects: 54
Study 25936892 — intervention group
Group type: EXPERIMENTAL
Intervention: NAV method
Number of subjects: 54
Study 25936892 — intervention group
Group type: COMPARATOR
Intervention: CT-guidance
Number of subjects: 54
Study 23895088 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA, n = 57)
Number of subjects: 179
Study 23895088 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI, n = 61)
Number of subjects: 179
Study 23895088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecologically-Based Family Therapy (EBFT, n = 61)
Number of subjects: 179
Study 23108883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear melanoma with ulceration
Number of subjects: 405
Study 23108883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonear melanoma with ulceration
Number of subjects: 405
Study 23108883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonear melanoma with thickness
Number of subjects: 405
Study 19734176 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (320/9 microg, one inhalation twice daily)
Number of subjects: 442
Study 19734176 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone (50/500 microg, one inhalation twice daily)
Number of subjects: 442
Study 17552386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon's space injection with a mixture of 3 mL of 2% lidocaine with hyaluronidase and 3 mL of 0.5% bupivacaine
Number of subjects: 46
Study 17552386 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sub-Tenon's space injection)
Number of subjects: 46
Study 15506554 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mL (26.25 mg) of 0.75% glucose-free ropivacaine
Number of subjects: 40
Study 15506554 — intervention group
Group type: COMPARATOR
Intervention: 4.5 mL (33.75 mg) of 0.75% glucose-free ropivacaine
Number of subjects: 40
Study 11510013 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG) induction at a dose of 1.5 mg/kg IV
Number of subjects: 71
Study 11510013 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone, 1,000 mg IV
Number of subjects: 71
Study 9576460 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal infusion of heparinized autologous blood
Number of subjects: 7
Study 9576460 — intervention group
Group type: COMPARATOR
Intervention: Egg white (control)
Number of subjects: 7
Study 8200260 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a therapy
Number of subjects: 36
Study 3499211 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside/cyclophosphamide pulses every eight weeks during continuation therapy
Number of subjects: 177
Study 3499211 — intervention group
Group type: COMPARATOR
Intervention: No ara-C/cyclo pulses
Number of subjects: 177
Study 30337597 — intervention group
Group type: EXPERIMENTAL
Intervention: 23‐valent PPV vaccination
Number of subjects: 2
Study 26056191 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg propafenone
Number of subjects: 12
Study 25299236 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A/Hepatitis B vaccinations
Number of subjects: 489
Study 25299236 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to care for Hepatitis C positive individuals
Number of subjects: 489
Study 23087298 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (two 5-min lower limb tourniquet occlusions)
Number of subjects: 80
Study 23087298 — intervention group
Group type: COMPARATOR
Intervention: Control (un-inflated tourniquet)
Number of subjects: 80
Study 23087298 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 80
Study 23087298 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 20192142 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 60
Study 20192142 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood injection
Number of subjects: 60
Study 20192142 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Number of subjects: 60
Study 18547692 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogenic acellular dermal matrix (ADM) graft during superficial or partial parotidectomy (n=64)
Number of subjects: 168
Study 18547692 — intervention group
Group type: COMPARATOR
Intervention: Superficial or partial parotidectomy alone (control group, n=104)
Number of subjects: 168
Study 15849842 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg three times a day)
Number of subjects: 20
Study 15849842 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg once a day)
Number of subjects: 20
Study 12585167 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional plus Salvia Injection (SI) intervention treated group (24 cases)
Number of subjects: 44
Study 12585167 — intervention group
Group type: COMPARATOR
Intervention: Conventional steroid treated group (20 cases)
Number of subjects: 44
Study 10368505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolytic agents used in abruptio placentae group (95 women, 73%)
Number of subjects: 236
Study 10368505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolytic agents used in placenta previa group (78 patients, 72%)
Number of subjects: 236
Study 10368505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolytic agents (combined patients: 171)
Number of subjects: 236
Study 10368505 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with tocolytic agents)
Number of subjects: 236
Study 7577279 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 50 mg
Number of subjects: 60
Study 7577279 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg
Number of subjects: 60
Study 7577279 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 60
Study 2040318 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (APSAC)
Number of subjects: 103
Study 2040318 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (Control)
Number of subjects: 103
Study 2040318 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined clinical scoring system
Number of subjects: 103
Study 2040318 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease of sigma-ST at 2 h post-treatment
Number of subjects: 103
Study 6786146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 9
Study 6786146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31060586 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA fragments from Lactococcus lactis strain Plasma (LC‐Plasma) with varying CpG motif copy numbers and G + C contents.
Number of subjects: 0
Study 31060586 — intervention group
Group type: EXPERIMENTAL
Intervention: LAB strains with high pDCs stimulatory activity.
Number of subjects: 0
Study 29022763 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for healthcare providers
Number of subjects: 46546
Study 29022763 — intervention group
Group type: COMPARATOR
Intervention: Doctors providing advice
Number of subjects: 46546
Study 29022763 — intervention group
Group type: COMPARATOR
Intervention: Risk status of patients
Number of subjects: 46546
Study 25943673 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electrical stimulation combined with a cooling vest (LFESCR)
Number of subjects: 8
Study 25943673 — intervention group
Group type: COMPARATOR
Intervention: Active recovery combined with a cooling vest (ACTCR)
Number of subjects: 8
Study 25943673 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency electrical stimulation (LFES)
Number of subjects: 8
Study 24252714 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 306
Study 24252714 — intervention group
Group type: COMPARATOR
Intervention: Referral to community-based resources
Number of subjects: 306
Study 22692704 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 386 at 10 mg/kg plus sorafenib 400 mg orally twice daily (arm A)
Number of subjects: 152
Study 22692704 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 386 at 3 mg/kg plus sorafenib 400 mg orally twice daily (arm B)
Number of subjects: 152
Study 22692704 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus sorafenib 400 mg orally twice daily (arm C)
Number of subjects: 152
Study 22692704 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label AMG 386 at 10 mg/kg plus sorafenib after disease progression (for patients in arm C)
Number of subjects: 152
Study 18977820 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa (acute challenge)
Number of subjects: 0
Study 18977820 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (acute challenge)
Number of subjects: 0
Study 16971054 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus abstinence-based incentives (N=209)
Number of subjects: 415
Study 16971054 — intervention group
Group type: COMPARATOR
Intervention: Usual care (N=206)
Number of subjects: 415
Study 14674961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation program (n = 14)
Number of subjects: 26
Study 14674961 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 26
Study 11503113 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium proximally porous-coated femoral component with hydroxyapatite-tricalcium phosphate coating
Number of subjects: 39
Study 11503113 — intervention group
Group type: COMPARATOR
Intervention: Titanium proximally porous-coated femoral component without hydroxyapatite-tricalcium phosphate coating
Number of subjects: 39
Study 9560874 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (ReVia, DuPont, Wilmington, DE)
Number of subjects: 30
Study 9560874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8062610 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight urinary albumin excretion rate (AER) determined by radioimmunoassay
Number of subjects: 13
Study 8062610 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial AER in the range of 53-76 micrograms/min
Number of subjects: 13
Study 8062610 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial AER > or = 53 or > or = 80 micrograms/min
Number of subjects: 13
Study 3068567 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 20
Study 3068567 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 20
Study 3068567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28816582 — intervention group
Group type: EXPERIMENTAL
Intervention: Conductive education (CE) course followed by conventional practice
Number of subjects: 21
Study 28816582 — intervention group
Group type: COMPARATOR
Intervention: Conventional practice (waiting list group)
Number of subjects: 21
Study 28816582 — intervention group
Group type: COMPARATOR
Intervention: Conventional practice (both groups)
Number of subjects: 21
Study 29953171 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clotrimazole powder (1% CP)
Number of subjects: 67
Study 29953171 — intervention group
Group type: COMPARATOR
Intervention: 1% clotrimazole cream (1% CC)
Number of subjects: 67
Study 24045856 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish return-to-work (RTW) program
Number of subjects: 3105
Study 24045856 — intervention group
Group type: COMPARATOR
Intervention: Ordinary sickness benefit management (OSM)
Number of subjects: 3105
Study 22691051 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective Birth at 37 weeks (n=116)
Number of subjects: 235
Study 22691051 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (n=119)
Number of subjects: 235
Study 20130487 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual estimation of blood loss with vital signs indicating instability (low blood pressure, high heart rate)
Number of subjects: 0
Study 20130487 — intervention group
Group type: COMPARATOR
Intervention: Visual estimation of blood loss without specific vital signs
Number of subjects: 0
Study 18494851 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (ETC inserted and fixed in the midline)
Number of subjects: 30
Study 18494851 — intervention group
Group type: COMPARATOR
Intervention: Group B (ETC inserted along the angle of the mouth and fixed laterally)
Number of subjects: 30
Study 15376818 — intervention group
Group type: EXPERIMENTAL
Intervention: CD‐ROM plus parent intervention
Number of subjects: 514
Study 15376818 — intervention group
Group type: EXPERIMENTAL
Intervention: CD‐ROM only
Number of subjects: 514
Study 15376818 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 514
Study 11137810 — intervention group
Group type: EXPERIMENTAL
Intervention: 3mg sodium nitroprusside in 10ml of 5% dextrose solution sprayed on the pedicle (Group I, n=42)
Number of subjects: 86
Study 11137810 — intervention group
Group type: COMPARATOR
Intervention: Half of the sodium nitroprusside solution sprayed and half injected into the pedicle (Group II, n=44)
Number of subjects: 86
Study 9919476 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 592
Study 9919476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 592
Study 8300691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephazolin (1 g single dose)
Number of subjects: 141
Study 8300691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 8300691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephazolin
Number of subjects: 141
Study 2902683 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol (10 mg, intravenously)
Number of subjects: 12